Impact of Smoking on Disease Activity and Inflammatory Biomarkers in Rheumatoid Arthritis Patients Treated with Infliximab

Abstract

Rheumatoid arthritis (RA) is a continual autoimmune disease which triggers inflammation of the joint fluid, physical harm to the joints over time, and problems spread throughout the body. Even if there are good biologic treatments like infliximab, many patients still fail to achieve their medical objectives. It becomes consequently necessary to identify modifiable factors associated with a poor inflammatory response. Smoking has been identified as a major environmental component affecting the severity of rheumatoid arthritis (RA) and treatment efficacy. The overall goal of this work was to assess the association between smoking and inadequate inflammatory response in rheumatoid arthritis patients, with emphasis on two fundamental biomarkers, namely matrix metalloproteinase-3 (MMP-3) and erythrocyte sedimentation rate (ESR). A cross-sectional comparative study was performed with 120 individuals categorized into three different categories: RA patients exhibiting an excellent response to infliximab, RA patients demonstrating an unfavorable response, and normal control subjects. The Disease Activity Level Score (DAS28) was used to determine the patients' health, and normal laboratory protocols were used to detect serum MMP-3 concentrations and ESR. The findings suggested that smokers had notably elevated levels of MMP-3 and ESR in comparison to non-smokers, especially within the negative response study population. Smoking was significantly more common in the poor-response group (80.0% vs. 7.1%,p<0.001) and was associated with higher MMP-3 and ESR levels (both p<0.001). Significant positive correlations were observed between smoking and ESR (r=0.762) as well as MMP-3 (r=0.645). Smoking had a significant connection with raised inflammatory concentration, heightened disease activity, and limited probability of reaching therapeutic objectives. Multi factor research confirmed the existence of smoking as was significantly associated with inadequate inflammatory response. In overall, smoking significantly exacerbates inflammatory pathways in rheumatoid arthritis and adversely affects the results of treatment. Monitoring and keeping an eye on biomarkers like MMP-3 and ESR might give healthcare providers beneficial data about how active a medical condition is. To enhance clinical results, quitting smoking should be a big part of managing RA.